SecBot SecBot
8-K ·Filed May 5, 2026

RVTY

REVVITY, INC.
MIXED
Impact 5/10
Horizonweeks Processed6mo ago SEC0000031791-26-000016
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The Q1 beat was modest and margins compressed, but the real story is the China IDX divestiture, a strategic portfolio simplification that removes ~6% of revenue but could improve margins. The pro forma guidance implies H2 deceleration from Q1's 6% pro forma organic growth to ~3-4% for the full year. Watch for definitive agreement details in Q2 and whether proceeds are used for debt reduction or further buybacks. The stock may trade range-bound until the divestiture closes in 2027.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$92.30
T+0 close · May 5, 2026 · via day close
Latest settled
+23.01%
T+60 · $113.54
Vs SPY
+20.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $92.30entry
  2. T+1 · 6mo ago +7.36%α +5.97% · $99.09
  3. T+5 · 6mo ago +7.58%α +5.60% · $99.30
  4. T+20 · 6mo ago +8.76%α +3.81% · $100.39
  5. T+60 · 4mo ago +23.01%α +20.27% · $113.54

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revvity reported Q1 2026 adjusted EPS of $1.06, beating the $1.02 consensus by 3.9%, on reported revenue of $711M (7% YoY growth, 3% organic). The company announced plans to divest its China Immunodiagnostics business (6% of 2025 revenue) for up to $200M and updated FY2026 pro forma guidance to $2.81-$2.84B revenue and $5.20-$5.30 adjusted EPS. While the quarter was solid, the divestiture introduces execution risk and the guidance implies a deceleration from Q1's pace, making the overall read-through mixed.

Key Financial Metrics

EPS
$1.06
est $1.02 · +3.9%
Revenue
$711.1M
est $704.2M · +1.0% · +7.0% YoY
Rating
beat
Guidance
$2.81B-$2.84B
maintained

Key Facts

  • Q1 2026 GAAP EPS from continuing operations: $0.37 (vs $0.35 YoY); adjusted EPS: $1.06 (vs $1.01 YoY)
  • Q1 2026 reported revenue: $711M (7% YoY growth); organic revenue growth: 3%; pro forma organic growth: 6%
  • Announced intention to divest China Immunodiagnostics business (~6% of FY2025 revenue) for up to $200M; LOI signed April 16, 2026; definitive agreement expected Q2 2026; close expected 2027
  • Updated FY2026 pro forma guidance: revenue $2.81-$2.84B, pro forma organic growth 3%-4%, pro forma adjusted EPS $5.20-$5.30
  • Prior FY2026 guidance (Feb 2026) was $2.96-$2.99B revenue and adjusted EPS $5.35-$5.45 on a reported basis; the new pro forma guidance excludes the China IDX business
  • Life Sciences segment revenue: $362M (+6% YoY); Diagnostics: $349M (+8% YoY)
  • Adjusted operating margin contracted to 23.6% from 25.6% YoY; GAAP operating margin was 10.7% vs 10.9%
  • Operating cash flow from continuing operations: $125.9M vs $134.1M YoY; share repurchases of $86.5M in Q1

Financial Impact

Divestiture of China IDX for up to $200M; business represented ~$171M of FY2025 revenue (6% of total). Pro forma guidance implies FY2026 revenue of $2.81-$2.84B, down from prior $2.96-$2.99B reported guidance due to the exclusion.

revenueepsoperating margincash flow

Risk Factors

  • Divestiture execution risk, definitive agreement not yet signed; regulatory approvals in China could delay or derail the deal
  • Pro forma guidance implies slowing organic growth in H2 2026 vs Q1's 6% pro forma pace
  • Adjusted operating margin declining YoY (23.6% vs 25.6%), cost pressures or mix shift
  • Operating cash flow declined 6% YoY to $125.9M
  • Restructuring charges of $10.7M in Q1 suggest ongoing cost-cutting

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
56% bullish (25 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000031791-26-000016
Document: q12026proformafinancialsta.htm0000031791-26-000016
Document: pki-20260505.htm0000031791-26-000016
Document: 0000031791-26-000016-index-headers.html0000031791-26-000016
Document: 0000031791-26-000016-index.html0000031791-26-000016
Document: 0000031791-26-000016.txt0000031791-26-000016
8-K Data (Synthetic)0000031791-26-000016

Track record

9 reports on RVTY

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +45.31% at T+60 after the Aug 4, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $150.78 Now $148.79 −1.32% settles Dec 15
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $156.51 Now $148.79 −4.94% settles Dec 14
  3. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $163.48 Now $148.79 −8.99% settles Dec 2
  4. Oct 15, 20264w ago Institutional Cluster Neutral 3/10 Entry $154.64 to $158.25 Now $148.79 −3.79% ▲ +2.33% +3.75% vs SPY
  5. Oct 7, 20265w ago SC 13G/A Bullish 4/10 Entry $153.60 to $159.43 Now $148.79 −3.13% ▲ +3.80% +5.13% vs SPY
  6. Sep 23, 20267w ago Insider Cluster Bearish 4/10 Entry $150.61 to $157.29 Now $148.79 +1.21% ▼ −4.43% −4.85% vs SPY
  7. Aug 4, 202614w ago 8-K Bullish 7/10 Entry $111.39 to $126.59 Now $148.79 +33.57% ▲ +13.65% +14.88% vs SPY
  8. May 5, 202627w ago 8-K Mixed 5/10 Viewing Entry $92.30 to $100.39 Now $148.79 +61.20% ▲ +8.76% +3.81% vs SPY
  9. Mar 16, 202635w ago DEFA14A Neutral 3/10 Entry $86.41 to $93.44 Now $148.79 +72.18% ▲ +8.13% +4.35% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Tue (17h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026